Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology
18. Dezember 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results
26. November 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS will include data from recent PK study alongside results of...
Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
31. Oktober 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Intelligent Bio Solutions has partnered with B2i Digital to execute an investor communications program.
Intelligent Bio Solutions Celebrates One Year Anniversary of Enhanced Workplace Safety with London-Based Real-Estate Developer, Mount Anvil
24. Oktober 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
INBS announces one year of enhanced workplace safety with Mount Anvil following the integration of fingerprint drug testing.
Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution
09. Oktober 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
INBS announces its distribution partnership with Spirit Group, an Australian, Indigenous-owned marketing and consulting agency.
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
27. September 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
INBS successfully completes in-clinic testing proposed to the FDA earlier this year in its clinical study plan.
Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission
05. September 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Intelligent Bio Solutions Inc. Reports 118% Year-Over-Year Growth in Customer Employee Base, Reaching an Estimated Total of 1.4 Million Employees
03. September 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a leader in non-invasive drug testing technology, today announced significant...
Intelligent Bio Solutions Inc. Highlights Growing Need for Drug Testing Solutions in Key Industries
13. August 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing prevalence of on-the-job drug use across critical sectors such as...
Intelligent Bio Solutions Strengthens UK Market Position with Addition of Key Manufacturing Accounts
09. Juli 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...